جست‌وجوی استاد و پژوهشگر

• Medicinal Chemistry
• Drug Discovery
• Infectious Diseases
• +۷ مورد دیگر

Dr Gemma Nixon is a Lecturer in the Department of Chemistry at the University of Liverpool with a joint appointment in the Institute of Translational Medicine. She leads a Medicinal Chemistry Research group focused on infectious disease drug discovery and chemical biology approaches, maintaining active collaborations with the Liverpool School of Tropical Medicine and clinical partners. Her educational background includes a PhD in Chemistry from the University of Liverpool (2006), followed by postdoctoral research at the same institution on endoperoxide antimalarials. She gained industry experience at Peakdale Molecular before returning to LSTM for malaria and tuberculosis drug development projects funded by Wellcome Trust, MRC, and Bill & Melinda Gates Foundation. Dr Nixon's research spans rational design of therapeutics targeting tuberculosis, malaria, filariasis, cryptococcal meningitis, and cancer. Her group employs chemical synthesis, computational modelling, and biological evaluation to develop novel agents including β-tubulin-binding benzimidazoles for fungal infections and PROTAC degraders for metastatic breast cancer and motor neurone disease. Current work emphasizes target validation through activity-based protein profiling and optimization of drug candidates for improved pharmacokinetics. Recent publications demonstrate consistent focus on antimalarial and antitubercular agents, with growing emphasis on cancer therapeutics. Her work bridges chemical innovation with biological validation, particularly in mechanism-of-action studies for novel scaffolds and combination therapies against drug-resistant pathogens. Her scientific recognition includes: Chemistry Biology Interface Horizon Prize (Royal Society of Chemistry, 2024) Fellow of the Higher Education Academy (2018) Associate Member of the Higher Education Academy (2013) She has secured substantial research funding including an MRC New Investigator Grant (2016-2019) for anti-fungal benzimidazoles, Wolfson Foundation support for nanoAFM-IR imaging (2024-2027), and Motor Neurone Disease Association funding for SOD1 degraders (2023-2027). Her supervised projects cover chemical proteomic probes, thiazolide antivirals, tetraoxane antimalarials, and fluorescent antimicrobial susceptibility tools. Dr Nixon leads the Medicinal Chemistry Research group within the Department of Chemistry, actively participating in MedChemNet leadership and university committees including REF selection and student admissions. Her collaborative network spans pharmacology, tropical medicine, and clinical research teams at Liverpool.

Vikas Chopraمشاهده پروفایل

استاد

• Glaucoma
• Minimally Invasive Glaucoma Surgery
• Ocular Imaging
• +۳ مورد دیگر

Dr. Vikas Chopra holds the Charles Stewart Warren and Hildegard Warren Endowed Research Chair at Doheny Eye Centers-UCLA and serves as a Professor in the Department of Ophthalmology at the David Geffen School of Medicine, University of California, Los Angeles. He is a recognized expert in glaucoma surgical techniques, particularly Minimally Invasive Glaucoma Surgery (MIGS) procedures, and specializes in high-resolution ocular imaging for early and precise glaucoma evaluation. His research interests focus on developing new laser and surgical therapies for glaucoma and improving outcomes of complex combined cataract/glaucoma procedures. Analysis of his recent publications reveals consistent contributions to glaucoma diagnostics, surgical innovation, and treatment protocols, with particular emphasis on optical coherence tomography applications, MIGS outcomes, and combined surgical approaches. His work frequently appears in leading ophthalmology journals including Ophthalmology and Current Opinion in Ophthalmology. Super Doctors, Southern California (2022-2025) Top Doctors, Los Angeles Magazine (2021, 2024) Dr. Chopra is actively involved in surgical training of new ophthalmologists and serves on the committee that develops the American Board of Ophthalmology certification examinations. His clinical work spans multiple locations including the Doheny Eye Center UCLA Arcadia and Doheny Eye Center/UCLA Health - Pasadena, with hospital privileges at Ronald Reagan UCLA Medical Center. He is fluent in English, Spanish, and Hindi, enhancing his ability to serve diverse patient populations.

Theresa M. Buschمشاهده پروفایل

استاد پژوهشی

• Photodynamic Therapy
• Tumor Microenvironment
• Radiation Oncology
• +۴ مورد دیگر

Theresa M. Busch, Ph.D., serves as Research Professor and Associate Director of Research in the Department of Radiation Oncology at the Perelman School of Medicine, University of Pennsylvania. Her work bridges translational cancer research and clinical applications, focusing on optimizing radiation-based therapies through mechanistic understanding of tumor microenvironment dynamics. Her educational background includes: B.S. in Biophysics from the University of Scranton (1993) Ph.D. in Biophysics from the University at Buffalo, Roswell Park Cancer Institute Division (1998) Dr. Busch's research investigates photodynamic therapy (PDT) and FLASH radiotherapy mechanisms, with emphasis on vascular function, tissue oxygenation, and immune dynamics. Her lab examines how heterogeneities in oxygen, photosensitizer distribution, and light fluence impact treatment efficacy, utilizing murine models, large animals, and human clinical trials to translate findings into improved therapeutic strategies. Analysis of her 2024-2025 publications reveals dominant trends in FLASH proton therapy for normal tissue sparing, PDT-immunotherapy combinations for mesothelioma, and nanotechnology-enhanced drug delivery . These works consistently address biophysical limitations in cancer treatment while advancing dosimetry techniques and microenvironmental modulation. Dr. Busch mentors graduate students and research specialists including Master's candidate Lyna Dinh. Her collaborative projects span: Photodynamic therapy optimization for solid malignancies FLASH radiotherapy mechanisms for reducing chronic toxicity Immune checkpoint blockade to counteract surgery-induced immunosuppression The Busch Lab, located at the Smilow Center for Translational Research, comprises Senior Research Investigator Anastasia Velalopoulou, Ph.D., and specialists Shirron Carter, Min Yuan, and Joann Miller. The team collaborates with the Clinical Research Unit and Radiation Biology division to advance translational studies in radiation oncology, with particular focus on prostate cancer, pleural mesothelioma, and head and neck cancers.

• Child and Adolescent Psychiatry
• Health Informatics
• Telehealth
• +۴ مورد دیگر

Pamela Hoffman, MD serves as Assistant Professor of Child Psychiatry at Yale's Child Study Center and Lecturer in Biostatistics at the Yale School of Public Health, with dual appointments in both departments. She joined Yale in January 2020 as the medical director of Telehealth Services at Yale New Haven Health Services and Yale Medicine, where she leads telehealth initiatives across ambulatory and inpatient settings. As Co-Training Director for the Masters program in Health Informatics, she plays a key leadership role in shaping the next generation of health informatics professionals. Yale School of Public Health - Department of Biostatistics Yale Child Study Center - Primary Appointment Yale Medicine - Medical Director of Telehealth Services Biomedical Informatics and Data Science section collaborator Dr. Hoffman's research focuses on the intersection of child psychiatry and health informatics, with particular emphasis on telehealth implementation, electronic health record optimization, and pediatric emergency psychiatric services. Her work explores how digital health technologies can improve access to mental healthcare for children and adolescents, particularly during crisis situations. She investigates the ethical dimensions of health information sharing, the impact of telehealth on quality of care, and the development of specialized EHR systems for child psychiatry. Her publication record demonstrates a clear progression from traditional child psychiatry toward health informatics innovation, with increasing focus on telehealth systems following the pandemic. The research shows strong clinical grounding combined with technological innovation, particularly in adapting digital health solutions for vulnerable pediatric populations. Her work often addresses system-level challenges in healthcare delivery while maintaining focus on individual patient care quality. Dr. Hoffman maintains active clinical responsibilities in the pediatric emergency department, where she evaluates children in behavioral health crisis. She collaborates extensively with Yale's Biomedical Informatics and Data Science section, bridging clinical practice with technological innovation. Her leadership in the Health Informatics MS program demonstrates her commitment to developing future professionals who can navigate both clinical and technical aspects of modern healthcare. Her educational background combines strong clinical training with specialized informatics expertise. She completed her psychiatry residency and child/adolescent psychiatry fellowship at Hofstra Northwell Health in NY, followed by an additional fellowship in Clinical Informatics at Yale/VA Connecticut Healthcare System. This unique combination of clinical psychiatry training and health informatics expertise positions her as a leader in the emerging field of digital mental health services.

Jon M Rudermanمشاهده پروفایل

دانشیار بالینی

• Ophthalmology
• Glaucoma
• Cataract Surgery
• +۳ مورد دیگر

Jon M Ruderman is a Clinical Associate Professor in the Department of Ophthalmology at Northwestern University Feinberg School of Medicine . He specializes in glaucoma and cataract surgical techniques, including combined procedures for coexisting conditions. Education: MD from Northwestern University Feinberg School of Medicine (1979). Training: Ophthalmology residencies at UC San Diego (1981) and University of Illinois Hospital (1983); Glaucoma fellowship at Emory University Hospital (1984). Research Interests: Focus on surgical innovations for glaucoma and cataract management, intraocular pressure reduction techniques, and comparative analysis of surgical approaches. His work bridges clinical practice with surgical optimization. Publications highlight trends in glaucoma-cataract co-management, aqueous humor dynamics, and surgical methodology. Key themes include combined procedures, topical/systemic drug interactions, and intraocular pressure control. Honors: Research Award, Heed Society (1983) Contact: Northwestern Medicine Arkes Family Pavilion Suite 1500, 676 N Saint Clair, Chicago, IL 60611. Hospital Affiliation: Northwestern Memorial Hospital.

• Child Trauma and Adversity
• Behavioral Health Systems
• Child Welfare Policy
• +۳ مورد دیگر

Christian M. Connell, Ph.D. is an Associate Professor of Psychiatry at Yale School of Medicine with a focus on trauma and adversity impacting child and adolescent populations. His research examines contextual risk factors and protective processes within child welfare and behavioral health systems. Ph.D. in Clinical-Community Psychology, University of South Carolina Predoctoral/Postdoctoral Fellow, The Consultation Center at Yale Dr. Connell's work emphasizes: Community-based interventions for traumatized children Family-focused approaches to child maltreatment recovery Advanced quantitative analysis of behavioral outcomes His research portfolio includes grants from: National Institute of Mental Health Administration for Children and Families Substance Abuse and Mental Health Services Administration Key research trends across publications: Systematic evaluation of child welfare practices Multivariate analysis of trauma outcomes Development of screening methodologies for adversity Interdisciplinary approaches combining psychology and policy Scientific recognition includes: NICHD Clinical Research Loan Repayment Program Senior Fellow at Connecticut Child Health Institute Faculty Fellow at Yale's Zigler Center Dr. Connell leads research initiatives at the Child Development & Epidemiological Research Lab and collaborates with Yale faculty on trauma-informed systems redesign.

• Cancer Pharmacology
• Molecular Biology
• Tumor Suppressor p53
• +۵ مورد دیگر

Sonia Lain is a Professor of Molecular Cancer Pharmacology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet in Stockholm, Sweden. She leads the "Discovery and Elucidation of the mechanisms of Action of Tumour Selective Compunds" research group, with part of her laboratory also located at Science for Life Laboratories in Stockholm. Her work focuses on developing novel cancer therapeutics through molecular pharmacology approaches targeting tumor suppressor mechanisms. Dr. Lain's educational and professional background includes: Doctoral studies in virology at the Centro de Biología Molecular de Madrid Postdoctoral work at the University of Gothenburg (Sweden) with an EMBO fellowship on oncoviruses Postdoctoral and group leader position at the University of Dundee (Scotland) where she reached Lecturer rank Docent at Karolinska Institutet (2012) Professor of Molecular Cancer Pharmacology at Karolinska Institutet (2015-present) Dr. Lain's primary research focuses on cancer pharmacology with special emphasis on tumor suppressor p53 and nucleotide metabolism. Her laboratory investigates how to activate p53 through various mechanisms, particularly by targeting dihydroorotate dehydrogenase (DHODH), an enzyme involved in pyrimidine ribonucleotide synthesis. Her groundbreaking work demonstrated that the tumor suppressor p53 can be activated by inhibiting its nuclear export, leading to the development of molecules that inhibit nuclear export for cancer treatment. Her team has discovered dozens of molecules that activate p53 through multiple molecular mechanisms, with current research focused on identifying and improving molecules that alter nucleotide synthesis for selective cancer therapy. Analysis of Dr. Lain's publication record reveals a strategic progression from fundamental molecular mechanisms to therapeutic applications. Her work shows how nucleotide metabolism, particularly pyrimidine synthesis through DHODH, can be exploited for cancer treatment. Recent research has expanded to include metabolic effects beyond direct cancer cell killing, such as impacts on glucose metabolism and immune function, demonstrating the complexity of targeting metabolic pathways in cancer. Her group has developed novel compounds like the HZ series that specifically target DHODH with promising therapeutic potential. Dr. Lain's research group includes several key members who contribute to the laboratory's work: Suhas Darekar - Senior Research Specialist Muhammad Mushtaq - Research Specialist The Lain laboratory operates within the Division of Tumor Biology at Karolinska Institutet, with facilities at both the main campus and Science for Life Laboratories. The group maintains extensive collaborations with other researchers at Karolinska Institutet and internationally, as evidenced by numerous co-authored publications. Their research integrates molecular biology, biochemistry, pharmacology, and cancer biology approaches to develop novel therapeutic strategies that selectively target cancer cells while preserving normal cell function, representing a promising direction in cancer treatment development.

Joris van Montfransمشاهده پروفایل

دانشیار

• Pediatric Immunology
• Primary Immunodeficiencies
• Genetic Disorders
• +۳ مورد دیگر

Dr. Joris van Montfrans is an Associate Professor of Pediatric Immunology at UMC Utrecht , specializing in primary immunodeficiencies and their long-term complications. He leads a multidisciplinary team integrating clinical practice and research, with a focus on genetic causes of immune disorders and optimizing diagnostic protocols. Medical degree: Rijks Universiteit Leiden PhD: Vrije Universiteit Amsterdam Clinical training: UMC Utrecht & Tygerberg Hospital, Cape Town Research Highlights: His work spans genetic screening for immunodeficiencies, immune-modifying interventions , and autoimmune complications in CVID . He serves as principal investigator for national studies on early genetic screening and autoimmune disease mechanisms. Clinical Leadership: Heads the combined departments of Pediatric Immunology, Infectious Diseases, Rheumatology, and Hematology at UMC Utrecht. Focuses on bridging clinical care with translational research to address unmet needs in pediatric immunology.

Marco Pieroniمشاهده پروفایل

دانشیار

• Medicinal Chemistry
• Infectious Diseases
• Tuberculosis Research
• +۵ مورد دیگر

Marco Pieroni is an Associate Professor of Medicinal Chemistry at the Food and Drug Department, University of Parma , where he has held a tenure-track position since 2012. His research focuses on medicinal chemistry for bacterial and parasitic infections , particularly Tuberculosis (drug-sensitive and resistant strains), with emphasis on non-essential targets and adjuvant therapies . He has also expanded into CNS diseases and immunology in recent years. PhD in Medicinal Chemistry (2007), University of Perugia Master in Pharmacy (2003), University of Perugia (summa cum laude) His work spans quinolone derivatives , carbonic anhydrase inhibitors , and pharmacological chaperones , with over 30 publications and multiple patents. He has supervised 4 PhD graduates and 2 current candidates, and received grants including a PRIN National Grant (2017) and Abilitazione Scientifica Nazionale for both Associate and Full Professor positions. Scientific Awards : 2022 FIL grant for European project valorization 2020 Abilitazione Scientifica Nazionale for Full Professor 2017 PRIN National Grant Co-PI 2011 NIH-funded postdoctoral fellow

• Exotic Animal Medicine
• Wildlife Surgery
• Wildlife Conservation
• +۳ مورد دیگر

Jordi Aguiló Gisbert is an Adjunct Professor at UCH-CEU's Faculty of Veterinary and Head of the Exotic Animal Service at the CEU Veterinary Clinical Hospital since 2014. He graduated in Veterinary Medicine from UCH-CEU in 2004 and has specialized in exotic animal medicine, zoo animal care, and wildlife conservation. His roles include academic coordination, TFG/TFM tribunal membership, student tutoring, and clinical teaching. His research interests focus on Medicine and surgery of exotic and wild fauna , with particular emphasis on pharmacology, critical care, diagnostic imaging, and disease ecology in non-traditional veterinary species. He actively contributes to AVEPA's Exotic Animal Surgery and Medicine Group (GMCAE) and is pursuing AVEPA accreditation in Exotic Animal Medicine. Recent publications and presentations highlight his work on antiparasitic treatments for small mammals (2019), surgical pleurodesis in ferrets (2019), anthelmintic trials in Hermann's tortoises (2019), avian emergency care (2019), thyroid surgery in king snakes (2018), and wildlife Leishmaniasis reservoirs in Spain (2018). He frequently participates in clinical conferences and educational programs. A dedicated member of the SAIGAS research group (Service for Analysis, Research, and Management of Wild Animals), he combines clinical practice with conservation advocacy, emphasizing optimal health conditions for exotic pets and public education on wildlife preservation.

Emine Sümeyra Turalı Emreمشاهده پروفایل

استادیار

• Chiral nanoparticles
• Antibacterial nanoparticles
• Extracellular vesicle capturing
• +۵ مورد دیگر

Dr. Emine Sümeyra Turalı-Emre is an Assistant Professor at the Institute of Biomedical Engineering, Bogazici University, where she joined in 2024. She combines expertise in nanotechnology, biomedical engineering, and data science to solve critical healthcare challenges. Previously, she was a Postdoctoral Research Fellow in Chemical Engineering at the University of Michigan (2021-2024) and completed her PhD in Biomedical Engineering from the same institution in 2021. Her educational background includes: PhD in Biomedical Engineering, University of Michigan, 2021 MSc in Biomedical Engineering, University of Michigan, 2015 BSc in Molecular Biology and Genetics, Istanbul University, 2008 Dr. Turalı-Emre's research focuses on engineering inorganic nanoparticles for applications such as drug and gene delivery, antibacterial and anticancer treatments, bone regeneration, and extracellular vesicle capturing for diagnostics. Her work spans chiral nanoparticles, antibacterial nanoparticles, extracellular vesicle capturing, AI-driven nanoparticle-protein interactions, drug and gene delivery systems, cancer therapies, and translational nanotechnology. She approaches biomedical challenges through multidisciplinary collaborations that bridge engineering, life sciences, and computer science. Her recent publications in leading journals like Advanced Materials, Matter, and PNAS demonstrate strong trends in chiral nanomaterials for diagnostics and therapeutics, antibacterial applications against biofilms and antibiotic-resistant bacteria, and the integration of artificial intelligence with nanotechnology. Her work shows a clear progression from fundamental nanoparticle synthesis to translational applications in healthcare. Scientific awards and recognitions include: BioInterfaces Research Community Innovator Award, 2024 Full Member, Sigma Xi, The Scientific Research Honor Society, 2024 Women in Science and Engineering, Cinda Sue Davis STEM Equity Leadership Award (Nominee), 2024 Women in Science and Engineering, Willie Hobbs Moore Achievement Award (Nominee), 2024 Selected Participant, AI in Science & Engineering Summer Academy, 2023 And several other prestigious awards and recognitions Dr. Turalı-Emre is actively involved in mentoring students and fostering interdisciplinary collaboration. She currently leads a TÜBİTAK-BİLGEM project developing an AI-driven database to optimize antibacterial nanoparticles for diagnostics and treatments, in collaboration with Dr. Betül Özateş from the Institute of Data Science and Artificial Intelligence. She has also contributed to Coulter Translational Research Partnership projects focused on extracellular vesicle capture, optimizing RNA isolation from biofilms, and developing antibacterial surfaces using chiral nanoparticles. Her laboratory provides a vibrant environment for undergraduate, graduate, and non-traditional students from various fields, including engineering, life sciences, and computer science, to conduct impactful research and contribute to transformative innovations in healthcare.

Seth M. Pollackمشاهده پروفایل

استاد

• cancer immunotherapy
• sarcoma research
• T cell-based therapies
• +۳ مورد دیگر

Seth M. Pollack, MD is Professor with Tenure at Northwestern University Feinberg School of Medicine, holding the Steven T. Rosen Professorship of Cancer Biology. He serves as Director of the Sarcoma Program and Co-Leader of the Cancer Immunology and Immunotherapy Initiative at the Robert H. Lurie Comprehensive Cancer Center. Dr. Pollack is an internationally recognized physician-scientist whose research focuses on overcoming resistance to T cell–based therapies in sarcomas. His laboratory investigates immune evasion mechanisms in 'immune-cold' sarcoma subtypes like MHC class I down-regulation, translating these findings into cytokine-based strategies, toll-like receptor activation, and rational checkpoint inhibitor combinations. Current NIH- and DoD-funded projects span TCR-therapy optimization, IL-12 gene delivery, NK cell–directed therapies, and tumor microenvironment modulation. His clinical trial portfolio demonstrates significant leadership, including serving as national chair for ECOG-ACRIN's EA7222 phase III trial of doxorubicin plus pembrolizumab for advanced undifferentiated pleomorphic sarcoma. Analysis of his recent publications reveals dominant themes in sarcoma immunotherapy, health disparities research, and radiomics-based prognostic modeling across multiple sarcoma subtypes. Dr. Pollack maintains influential leadership positions including service on the NCCN Soft Tissue Sarcoma and GIST Guidelines Panels, the National Leiomyosarcoma Foundation Executive Committee, and medical advisory boards of the Sarcoma Alliance and Desmoid Tumor Research Foundation. He serves as Senior Editor for Molecular Cancer Therapeutics and frequently contributes to the Journal of Clinical Oncology. As principal investigator for multiple active clinical trials including the Northwestern Sarcoma Biorepository (STU00218245), COG AOST2032 for osteosarcoma, and global phase III trials for leiomyosarcoma and GIST, Dr. Pollack directs substantial research funding from NIH and DoD sources. His laboratory actively develops CAR-T immunotherapy approaches using canine sarcoma models and investigates the immune microenvironment of synovial and myxoid sarcomas.

Jessica W Templerمشاهده پروفایل

دانشیار

• Epilepsy
• Neuro-Oncology
• Clinical Neurophysiology
• +۳ مورد دیگر

Jessica W Templer, MD is an Associate Professor in Neurology and Neurological Surgery at Northwestern University's Feinberg School of Medicine, specializing in Epilepsy/Clinical Neurophysiology with board certifications in Neurology, Clinical Neurophysiology, and Epilepsy. Her clinical practice integrates epilepsy care with neuro-oncology at Northwestern Medicine affiliates including Central DuPage Hospital, Lake Forest Hospital, and Northwestern Memorial Hospital. Her educational journey comprises: MD from Chicago Medical School (2010) Internal Medicine Internship at Rush University (2011) Neurology Residency and Chief Medical Resident at Rush University (2014) Neurophysiology Fellowship at Northwestern Feinberg School of Medicine (2015) Dr. Templer's research pioneers the intersection of epilepsy and brain tumors, focusing on tumor-related seizure mechanisms, standardized assessment tools for glioma trials, and minimally invasive surgical interventions. Her work bridges clinical neurophysiology with neuro-oncology to optimize seizure control and preserve neurological function in complex cases, particularly through RANO-TREAT development and excitatory milieu investigations. Recent publications (2025) reveal a cohesive research trajectory centered on tumor-related epilepsy, combining clinical trial methodology (RANO-TREAT), molecular mechanisms in glioma, surgical innovation, and technical standardization. These works collectively advance precision medicine approaches for brain tumor patients with epilepsy across neuro-oncology, surgical neurology, and clinical neurophysiology domains. Honors include consecutive Castle Connolly recognitions as Exceptional Women in Medicine and Chicago Top Doctor (2023-2025), the Weill Award for Experimental Neuropathology (2022), and multiple teaching excellence awards from medical students and epilepsy fellows. Her Gold Humanism Honor Society membership (2010) underscores enduring commitment to patient-centered care. As an educator, she mentors medical students through Northwestern's College Mentor program, trains epilepsy fellows (earning their Teaching Award in 2018), and shapes national curricula via the American Neurological Association's Education Innovation Committee and ACNS Resident Education Committee. Her leadership in the Tumor-related Epilepsy Special Interest Group drives collaborative research frameworks. Dr. Templer co-leads the RANO seizure working group developing clinical trial standards, chairs professional committees advancing neurophysiology guidelines, and serves on the Epilepsy Foundation of Chicago's Advisory Board. Her editorial role at Epilepsy & Behavior Reports amplifies translational research impact across neurological care systems.

Benjamin Vincentمشاهده پروفایل

دانشیار

• Systems Tumor Immunology
• Immunogenomics
• Anti-Tumor Immunity
• +۶ مورد دیگر

Dr. Benjamin Vincent is an Associate Professor in the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Medicine. He serves as Principal Investigator of the Vincent Lab, which is part of the UNC Lineberger Comprehensive Cancer Center, an NCI-designated Cancer Center. Dr. Vincent is also co-chair of The Cancer Genome Atlas Immune Response Working Group and affiliated with the UNC Curriculum in Bioinformatics and Computational Biology. Undergraduate: University of North Carolina at Chapel Hill Medical School: University of North Carolina at Chapel Hill Residency: University of North Carolina at Chapel Hill Fellowship: University of North Carolina at Chapel Hill Dr. Vincent's research focuses on systems tumor immunology and immunogenomics, with particular emphasis on understanding anti-tumor immunity and translating these findings into curative immunotherapy strategies. His interdisciplinary laboratory combines experimental and computational approaches to study mechanisms of response versus resistance to tumor antigen vaccination and cellular immunotherapies in humans and murine model systems. Key research themes include understanding tumor immunobiology, developing novel immunogenomics tools, investigating response and resistance to combination immunotherapy, and targeting neoantigens and minor histocompatibility antigens for personalized immunotherapy. His work has highlighted the importance of antigen-specific B cell responses in breast cancer, bladder cancer, and other solid tumors, and has made significant contributions to identifying molecular subtype-specific differential immune responses. Analysis of Dr. Vincent's recent publications reveals a strong focus on translational cancer immunology, with particular emphasis on bladder cancer, breast cancer, and immunogenomics approaches. His work frequently explores the tumor microenvironment, immune checkpoint inhibitors, neoantigen discovery, and biomarkers for predicting treatment response. The publications demonstrate a consistent trajectory of moving basic immunological discoveries toward clinical applications, with increasing emphasis on computational approaches to analyze complex immunological datasets. Yang Family Biomedical Scholars Award, UNC School of Medicine, 2023-24 Biological and Biomedical Sciences Faculty Mentor Award, UNC-Chapel Hill, 2022 Invited speaker, Immuno-Oncology Young Investigators Forum, 2016 Pope Clinical Fellow Award, Lineberger Comprehensive Cancer Center, 2015 Outstanding Fellow Award, North Carolina Oncology Association, 2015 Dr. Vincent actively collaborates with clinicians and scientists across multiple disciplines, as evidenced by his involvement in numerous clinical trials including LCCC1525 (PD-1 inhibition following regulatory T cell depletion in metastatic triple negative breast cancer), LCCC1520 (adjuvant gemcitabine/cisplatin chemotherapy in bladder cancer), and LCCC1522 (with high-dose cytarabine in relapsed acute myeloid leukemia). His laboratory has developed multiple innovative tools for immune repertoire analysis and neoantigen prediction, and he serves as co-chair of The Cancer Genome Atlas Immune Response Working Group, indicating significant recognition within the cancer immunology community. The Vincent Lab operates as an interdisciplinary experimental and computational immunology group within the UNC Lineberger Comprehensive Cancer Center. The lab utilizes murine models of bladder cancer developed by William Kim to study differential immune responses and mechanisms of response versus resistance to immunotherapy. They have developed novel statistical techniques for T cell receptor and B cell receptor repertoire analysis, approaches for immune gene signature analysis, and pipelines for neoantigen prediction. The lab actively collaborates with the LCCC Mouse Phase I Unit and the Parrott Laboratory, creating a robust translational research environment that bridges basic science with clinical applications.

• Cancer Immunotherapy
• Oncolytic Virotherapy
• Gene Therapy
• +۳ مورد دیگر

Tatiana Kudling is a Doctoral Researcher at the Doctoral Programme in Clinical Research at the University of Helsinki, focusing on advanced cancer immunotherapy approaches using oncolytic adenoviruses. Her work explores gene-modified viral vectors encoding cytokines like TNFα and IL-2 to enhance immune responses against solid tumors. Email: tatiana.kudling@helsinki.fi Research Interests : Cancer immunotherapy, oncolytic virology, cytokine gene therapy, tumor microenvironment modulation, and immune checkpoint inhibitors. Her studies aim to overcome resistance to immunotherapies through viral vector engineering and combination strategies. Publication Trends : Over 28 research outputs (2017–2025) centered on oncolytic adenovirus applications in melanoma, ovarian, pancreatic, and renal cancers. Key themes include PD-L1 inhibition , Lymphocyte activation , and biomarker discovery for treatment monitoring. Collaborations : Co-authored with leading researchers in virotherapy (e.g., A. Hemminki, A. Kanerva) and immuno-oncology (e.g., M. Donia, J.M. Santos). Involved in clinical trials like PROTA (platinum-resistant ovarian cancer) and TUNIMO (solid tumors).